
    
      This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled,
      parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic
      suspension versus vehicle in subjects with dry eye disease.
    
  